Month: March 2022

Company to host investor update call Thursday, April 7, at 4:30 p.m. ET BOSTON, March 31, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial results for 2021 and recent business progress. “2021 was a foundational year for TransCode, highlighted by our successful IPO on Nasdaq in July,” said Michael Dudley, co-founder, president and CEO of TransCode. “With resources from the IPO, as well an important Small Business Innovation Research (SBIR) grant, we drove significant progress across the organization, including key additions to our team that bring valuable expertise, and continued advancement of our lead candidate and our preclinical development programs. We are now building on this foundation as we move toward...

Figure 1 Property map showing the location of Moribala Permit and the two target trends..Figure 2 Location of air core drilling and significant drill intercepts on the Moribala permit.Target Structure Runs at Least 6 km Along Strike TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Compass Gold Corp. (TSX-V: CVB) (Compass or the Company) is pleased to provide an update on the recently completed first-pass drilling on four areas on the new Moribala permit, located on the Company’s Sikasso Property in Southern Mali (Figure 1). Highlights:Initial shallow drilling (43-holes/2,110 m) on four prospects on Moribala permit identified a wide zone of shallow gold mineralization associated with the Moribala fault at DafarabaBest intercept: 21 m @ 0.50 g/t Au (from surface), incl. 7 m @ 1.01 g/t Au (from surface).Dafaraba mineralization...

SALT LAKE CITY, March 31, 2022 (GLOBE NEWSWIRE) — OMNIQ Corp. (NASDAQ: OMQS) (“OMNIQ” or “the Company”), a provider of Supply Chain and Artificial Intelligence (AI)-based solutions, today announced its financial results for the three months and full year ended December 31, 2021. OMNIQ’s 2021 momentum:Company up listed to NASDAQ in September 2021. Close to $100,000,000 annual revenue run rate marks a significant milestone as fourth quarter revenue increased to $24.9 Million. Company acquired 77% of Dangot Computers Ltd., a leader in providing sophisticated solutions of automation for Hospitals, Restaurants, Supermarkets, Government Institutions and others. Synergy with Dangot generated immediate joint projects with OMNIQ’s AI solutions. OMNIQ’s Q Shield’s AI based turnkey law enforcement solution offered to municipalities is experiencing positive...

SOMERVILLE, Mass., March 31, 2022 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today reported fourth quarter and full year 2021 financial results and provided business updates. “Finch achieved many significant milestones in 2021, including new clinical data readouts that support our lead product candidate, CP101, for the prevention of recurrent C. difficile infection and the advancement of our TAK-524 ulcerative colitis development program to Takeda for further development. Following a strategic review of our pipeline, we have decided to focus on our C. difficile and autism programs, in addition to our partnership...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATESRevenues for the year up 24% to $47.8 million and for the fourth quarter up 27% to $13.9 million over the comparable periods last year. Successful execution of acquisition strategy in 2021, including the acquisition of Khure Health Inc. (“Khure”) for up to $12.6 million, and the Polyclinic Group of Companies (“Polyclinic”) for $7.1 million, boosting Corporate Health and Health Technology segments. Record year for telehealth sessions, with nearly 300,000 patients accessing MCI’s high-performance healthcare network via telephone consults and MCI Connect, MCI’s virtual care delivery platform. MCI’s Corporate Health Services delivers a record year, adding 87 new customers and experiencing more than 70% revenue growth year-on-year. Patient volumes up 12%...

Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced financial results for the year ended December 31, 2021. “We managed to achieve all of our internal objectives for 2021,” stated Dennis J. Carlo, Ph.D., President and Chief Executive Officer of Adamis Pharmaceuticals. “Included among them, we began enrolling patients in a Phase 2/3 clinical trial evaluating Tempol as a treatment of COVID-19, resubmitted our NDA for ZIMHI and subsequently received FDA approval.” Product and Pipeline Updates and Other Corporate Developments ZIMHIIn October 2021, the U.S....

Company’s NWASSA financial technology platform more than doubles revenue year-on-year NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) — via InvestorWire – Tingo Inc, (OTC Markets: TMNA) (“Tingo” or the “Company”) has filed its annual report on Form 10-K, wherein the Company reported its audited financial results for the year ended Dec. 31, 2021. Given that the Company’s audited results reflected a partial operating year resulting from the acquisition of its principal operating subsidiary, Tingo Mobile plc (“Tingo Mobile”), in August 2021, the Company’s annual report also included proforma financial results for the entire year for Tingo Mobile.   On a proforma basis, the Company reported 2021 revenues and operating income for Tingo Mobile of $865.9 million and $327.1 million, respectively, compared to 2020 revenues and operating income...